Freund KB, Zweifel SA, Engelbert M (2010) Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30(9):1333–1349

Article  PubMed  Google Scholar 

Jaffe GJ, Martin DF, Toth CA et al (2013) Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120(9):1860–1870

Article  PubMed  Google Scholar 

Park DH, Sun HJ, Lee SJ (2017) A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Int Ophthalmol 37(5):1205–1214

Article  PubMed  Google Scholar 

Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M (2015) Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci 56(11):6501–6505

Article  PubMed  Google Scholar 

Heier JS, Brown DM, Chong V et al (2012) VIEW 1 and VIEW 2 Study Groups. intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119:2537–48

Article  PubMed  Google Scholar 

CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908

Article  Google Scholar 

Nair AA, Finn AP, Sternberg P Jr (2022) Spotlight on faricimab in the treatment of wet age-related macular degeneration: design, development and place in therapy. Drug Des Devel Ther 29(16):3395–3400

Article  Google Scholar 

Horner F, Lip PL, Mohammed BR, Fusi-Rubiano W, Gokhale E, Mushtaq B, Chavan R (2021) Comparing effectiveness of three different anti-VEGF treatment regimens for neovascular age-related macular degeneration: two years’ real-world clinical outcomes. Clin Ophthalmol 15:1703–1713

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Chioreso C, Schweizer ML, Abràmoff MD (2017) Effects of aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis of observational comparative studies. Invest Ophthalmol Vis Sci 58(13):5616–5627

PubMed  PubMed Central  Google Scholar 

Lee JE, Shin JP, Kim HW, Chang W, Kim YC, Lee SJ, Chung IY, Lee JE (2017) VAULT study group. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study. Graefes Arch Clin Exp Ophthalmol 255(3):493–502

Article  PubMed  Google Scholar 

Kusenda P, Caprnda M, Gabrielova Z, Kukova N, Pavlovic S, Stefanickova J (2024) Understanding loss to follow-up in AMD patients receiving VEGF inhibitor therapy: associated factors and underlying reasons. Diagnostics (Basel) 14(4):400

Article  PubMed  Google Scholar 

Obeid A, Gao X, Ali FS, Aderman CM, Shahlaee A, Adam MK, Kasi SK, Hyman L, Ho AC, Hsu J (2018) Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol 136(11):1251–1259

Article  PubMed  PubMed Central  Google Scholar 

Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, Morlet N, Hunyor AP, Essex RW, Arnold JJ, Gillies MC (2018) fight retinal blindness study group. two year outcomes of “treat and extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina 38(1):20–28

Article  PubMed  Google Scholar 

Holz FG, Tadayoni R, Beatty S et al (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220–226

Article  PubMed  Google Scholar 

Schmucker CM, Rücker G, Sommer H, Virgili G, Loke YK, Oeller P, Agostini H, Ehlken C (2015) Treatment as required versus regular monthly treatment in the management of neovascular age-related macular degeneration: a systematic review and meta-analysis. PLoS ONE 10(9):e0137866

Article  PubMed  PubMed Central  Google Scholar 

Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF (2014) CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121(1):150–161

Article  PubMed  Google Scholar 

Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y (2020) ALTAIR investigators efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-Week Findings from ALTAIR: a randomized controlled trial. Adv Ther 37(3):1173–1187

Article  PubMed  PubMed Central  Google Scholar 

Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S (2013) Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol 97(11):1443–1446

Article  PubMed  Google Scholar 

Nielsen JS, Roberts CL, Saggau DD, Alliman KJ (2023) High-dose aflibercept for neovascular AMD and DME in suboptimal responders to standard-dose aflibercept. J Vitreoretin Dis 7(2):116–124

Article  PubMed  PubMed Central  Google Scholar 

Eylea HD (AFLIBERCEPT) injection 8 mg approved by FDA for treatment of wet age-related macular degeneration (wamd), diabetic macular edema (DME) and Diabetic Retinopathy (DR). Regeneron Pharmaceuticals Inc. August 18, 2023. Accessed August 19, 2023. https://investor.regeneron.com/news-releases/news-release-details/eylea-hd-aflibercept-injection-8-mg-approved-fda-treatment-wet.

You QS, Gaber R, Meshi A, Ramkumar HL, Alam M, Muftuoglu IK, Freeman WR (2018) High-dose high-frequency aflibercept for recalcitrant neovascular age-related macular degeneration. Retina 38(6):1156–1165

Article  PubMed  Google Scholar 

Jaggi D, Nagamany T, Ebneter A, Munk M, Wolf S, Zinkernagel M (2022) Aflibercept for age-related macular degeneration: 4-year outcomes of a “treat-and-extend” regimen with exit-strategy. Br J Ophthalmol 106(2):246–250

Article  PubMed  Google Scholar 

Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J (2020) Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies. Adv Ther 37(1):300–315

Article  PubMed  Google Scholar 

Panchmatia HR, Clements KM, Hulbert E, Eriksson M, Wittrup-Jensen K, Nilsson J, Weinstein MC (2016) Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden. Acta Ophthalmol 94(5):441–8

Article  PubMed  Google Scholar 

Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, Schulze A, Schmelter T, Schmidt-Ott U, Zhang X, Vitti R, Chu KW, Reed K, Rao R, Bhore R, Cheng Y, Sun W, Hirshberg B, Yancopoulos GD, Wong TY (2024) PULSAR Investigators Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403(10432):1141–1152

Article  PubMed  Google Scholar 

Broadhead GK, Keenan TDL, Chew EY, Wiley HE, Cukras CA (2022) Comparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 260(7):2239–2247

Article  PubMed  Google Scholar